Management Team

Kiadis Pharma has a seasoned senior leadership team consisting of highly experienced industry professionals with complementary skill sets. The team has an established track record in pursuing drug discovery and development as well as deal-making objectives, both in smaller biotechnology companies and in large pharmaceutical companies.

Arthur Lahr

Chief Executive Officer

Arthur Lahr joined Kiadis Pharma in 2017 and is Chief Executive Officer. Mr. Lahr brings more than 20 years of experience within the healthcare sector to Kiadis Pharma. Before joining Kiadis Pharma, he was chief strategy officer and a member of the management committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Prior to Crucell, he was a consultant at McKinsey & Company and an engineer at Unilever.  Mr. Lahr holds a Master’s degree in Applied Physics from the University of Delft, The Netherlands, and a MBA from INSEAD, France.

Ray Barlow

Chief Business Officer

Ray Barlow joined Kiadis in 2020 and is Chief Business Officer. With more than 20 years of experience in the biopharmaceutical industry, Dr. Barlow has served in various leadership roles including most recently as chief executive officer at e-therapeutics PLC where he led the turnaround of the business, including generating its first commercial deals. Previously, Dr. Barlow worked at Amgen as executive director of corporate development leading a number of significant transactions over a 5-year period and, prior to that, at Crucell Vaccines where he led business deals in infectious diseases and vaccines. Prior to joining Crucell, he founded and led his own business, BD Solutions Ltd, advising clients on corporate development and commercialization strategies. Dr. Barlow started his career at AstraZeneca where he held a number of senior R&D, Business Development and Commercial roles over a 12-year period. Dr. Barlow holds a Ph.D. in macromolecular science from the University of Manchester, UK, a BSc (Hons) in Chemistry from the University of Leeds, UK, and an MBA from Manchester Business School, UK.

Dirk De Naeyer

Chief Operations Officer

Dirk De Naeyer joined Kiadis Pharma in 2018 and is Chief Operations Officer. Mr. De Naeyer brings nearly 20 years of experience leading operations in both clinical and commercial-stage biotechnology companies. Prior to joining Kiadis Pharma, he was at Janssen Pharmaceuticals where he spent 14 years in various leadership positions. Most recently, Mr. De Naeyer was co-lead for the integration of Actelion into Janssen. Prior to that, he was the head of the Janssen Global Clinical Operations team and held multiple supply chain and operations leadership positions. This included heading up the Janssen Clinical Supply Chain, overseeing all active pharmaceutical ingredient (API) and Drug Product manufacturing, Packaging and Distribution for Janssen R&D, which covered Small Molecules, Biologics and Stem Cell therapies. Mr. De Naeyer joined Janssen after five years at McKinsey & Company. He holds a degree in Engineering from the KU Leuven, Belgium, and a MBA from the University of Chicago. Mr. De Naeyer is a Belgian citizen.

Robert Friesen

Chief Scientific Officer

Robert Friesen, PhD, joined Kiadis Pharma in 2019 and is Chief Scientific Officer. Dr. Friesen has more than 20 years of experience in the biopharmaceutical industry leading multiple Research and Development organizations. Dr. Friesen joined Kiadis Pharma from Ablynx where he was CSO until its acquisition by Sanofi. Prior to Sanofi, he served as senior vice president of ProQR Therapeutics, a clinical stage biotechnology company, heading the science and early development division. Prior to joining ProQR Therapeutics, Dr. Friesen worked at Janssen BioTherapeutics, a Johnson & Johnson Company, as global head of biologics research, and at the Crucell Vaccine Institute, a Johnson & Johnson Company, as vice president preclinical and clinical research. Before Crucell Vaccine Institute, he was head of preclinical & early clinical development at MorphoSys.

Margot Hoppe

General Counsel & Corporate Secretary

Margot Hoppe was our General Counsel & Corporate Secretary from 2008 through 2018. On June 1, 2020, Ms. Hoppe rejoined us as an employee, again in the position of our General Counsel & Corporate Secretary. She has over 20 years of experience in corporate legal affairs and worked for various biotechnology companies including Gist-Brocades and Koninklijke DSM N.V. Ms. Hoppe holds a Master’s degrees in law and political science from the Erasmus University of Rotterdam, the Netherlands.

Martine Nolan

Senior Vice President, Quality

Martine Nolan joined Kiadis Pharma in 2019 and is Senior Vice President, Quality. Ms. Nolan brings over 20 years of experience in commercial quality and manufacturing in the pharmaceutical sector. She joined Kiadis Pharma from Amgen where she served as regional head of quality operations at the Dublin, Ireland and Breda, Netherlands sites. Prior to that Ms. Nolan served as executive director for international quality, Turkey, Middle East & Africa. Before joining Amgen, Ms. Nolan held several positions of increasing responsibility in quality operations at Schering-Plough (Merck) in Ireland, Singapore and US. Ms. Nolan holds a MSc in Cellular Physiology from University College Cork and a BSc in Biochemistry from University College Dublin.

Andrew Sandler

Chief Medical Officer

Andrew Sandler joined Kiadis Pharma in 2017 and is Chief Medical Officer. Dr. Sandler has over 20 years of experience within the healthcare industry dedicated to hematologic malignancies and solid tumors. Prior to joining Kiadis Pharma, he was senior vice president, medical affairs, at Medivation (now part of Pfizer). Prior to that he was CMO at Dendreon Pharmaceuticals and Spectrum Pharma. He has also held senior-level positions with several leading biotechnology and pharmaceutical companies, including Bayer Healthcare, Berlex and Seattle Genetics. Dr. Sandler obtained his MD from Mount Sinai School of Medicine, New York and completed a fellowship in medical oncology at University of California San Francisco. A US citizen, Dr. Sandler is a board certified medical oncologist and has treated many patients with hematologic malignancies, including bone marrow transplant patients.

Govert Schouten

Head of Innovation

Govert Schouten joined Kiadis in 2020 and is Head of Innovation. Dr. Schouten brings nearly 25 years of experience in developing and implementing strategies to build businesses and create value. Prior to joining Kiadis, Dr. Schouten was the founder of Idmon Consulting B.V., a consulting firm providing corporate development, strategy and business development services to the pharmaceutical and biotechnology industry. Previously, Dr. Schouten was co-founder and chief business officer of myTomorrows (Impatients N.V.), chief executive officer of Mucosis B.V., and vice president, head of business development and member of the executive committee of Crucell Vaccines. Dr. Schouten holds a Master’s degree in biomedical sciences and a PhD in tumor virology from Leiden University, the Netherlands.

Amy Sullivan

Chief Strategy Officer

Amy Sullivan joined Kiadis in January 2019 as senior vice president, corporate affairs and in December 2019 was promoted to Chief Strategy Officer responsible for fundraising, investor relations, public affairs and corporate communications. Ms. Sullivan has more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. She joins Kiadis Pharma from Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company’s first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmacueticals and Genencor International. Ms. Sullivan has a Bachelor of Science degree in business from Salem State University and a MBA from Bentley University.

Paul van Hagen

Senior Vice President Finance

Paul van Hagen joined Kiadis in 2018 as vice president, finance and in December 2019 was promoted to Senior Vice President Finance and is responsible for the finance function. Mr. Van Hagen brings over 20 years of financial management expertise to Kiadis. Prior to joining Kiadis, Mr. van Hagen provided financial advice to various companies in the life science industry and served as chief financial officer of Xeltis, a medical device company. Prior to Xeltis, he held senior financial management positions at Prosensa and Crucell, both publicly listed Companies. Mr. van Hagen worked as a Senior Manager with Ernst & Young and was responsible for various international audit engagements. Mr. van Hagen is a certified public accountant and holds a Master’s degree in Business Economics from the University of Groningen in The Netherlands. Mr. van Hagen is a Dutch citizen.

Arthur Lahr

Chief Executive Officer

Ray Barlow

Chief Business Officer

Dirk De Naeyer

Chief Operations Officer

Robert Friesen

Chief Scientific Officer

Margot Hoppe

General Counsel & Corporate Secretary

Martine Nolan

Senior Vice President, Quality

Andrew Sandler

Chief Medical Officer

Govert Schouten

Head of Innovation

Amy Sullivan

Chief Strategy Officer

Paul van Hagen

Senior Vice President Finance